drug sponsor affiliation screening and import controls

Summary#

This bill requires the Department of Health and Human Services (acting through the FDA) to review certain drug applications tied to Chinese entities and to block approval or imports when the sponsor or holder is found to be affiliated with the People’s Republic of China (PRC), the Chinese Communist Party (CCP), or the People’s Liberation Army (PLA). It also directs U.S. Customs and Border Protection to refuse and destroy imports of drugs on a list provided by HHS, with a narrow waiver for drug shortages. The stated broad goal is to reduce U.S. reliance on pharmaceuticals controlled by Chinese-affiliated organizations.

• Main change: FDA must review drug applications submitted on or after enactment by sponsors that are Chinese entities and must not approve any such application if the sponsor is determined to be PRC-, CCP-, or PLA-affiliated.
• Retroactive review: FDA must also review applications submitted between January 1, 2016 and the day before enactment to identify any sponsors or approved-application holders that are PRC-, CCP-, or PLA-affiliated.
• Imports refused: HHS must give Customs a list of drugs whose sponsor or approved-application holder is determined affiliated; Customs must refuse and destroy those imported drugs, unless a shortage waiver applies.
• Compliance path: Sponsors or approved-application holders on the list may try to show they are no longer affiliated or must sell the approved application to a non-affiliated entity within 180 days; they get an opportunity to appear before the Secretary.
• Funding: The bill authorizes $5,000,000 to carry out these provisions.

What it means for you#

• Drug companies and sponsors

  • If your company is organized under PRC law or is otherwise subject to PRC jurisdiction, the FDA will review your drug applications for possible affiliation with the PRC, CCP, or PLA.
  • If the FDA finds your company is affiliated as defined in the bill, new drug applications submitted after enactment cannot be approved.
  • If an already approved application is found to be affiliated, imports of that drug may be refused and the company would have 180 days to sell the approved application to a non-affiliated buyer or to show it is no longer affiliated.

• Importers and distributors

  • Customs will refuse and destroy drugs on the HHS list when those drugs appear to be linked to affiliated sponsors or holders. Importers will lose the shipment and will not be able to export it back under the bill’s default rule.

• Patients and health care providers

  • Some drugs could be refused at the border and removed from U.S. distribution if the sponsor or holder is found affiliated.
  • A waiver can allow importing such a drug when the Secretary and Customs determine refusing it would create or worsen a drug shortage. This could limit but not eliminate shortages.

• Federal agencies

  • FDA must coordinate with HHS’s Office of National Security for the required reviews.
  • Customs must act on the list and destroy refused imports unless a waiver is used.

• General public

  • This law targets the relationship between drug sponsors/holders and certain PRC-linked entities. It does not directly ban drugs based on where they are manufactured unless the sponsor/holder is determined affiliated under the bill’s tests.

Expenses#

Estimated public cost: Authorization of $5,000,000 to carry out the bill.

• The bill authorizes $5,000,000 to be appropriated and available until spent to implement the review and related activities.
• The bill does not include a broader fiscal estimate for ongoing FDA, HHS, or Customs staff costs, or for costs tied to additional inspections, legal reviews, or enforcement beyond the authorized amount.
• No publicly available information on expected costs to businesses, importers, or secondary costs to hospitals, pharmacies, or state governments in the bill text.

Proponents' View#

• The bill appears intended to reduce U.S. dependence on pharmaceutical products controlled by entities that receive support from the PRC, CCP, or PLA.
• Supporters may argue this approach increases national security oversight of drugs tied to foreign governments or military-linked entities.
• The bill creates a clear compliance path (selling the approved application or proving non-affiliation) rather than an immediate permanent ban, which could be seen as a way to transfer control to non-affiliated firms.
• The waiver for drug shortages aims to limit harm to public health when refusing imports would worsen supply problems.

Opponents' View#

• One concern is that the bill could disrupt supply chains and reduce access to some medicines if approved drugs are placed on the refusal list and cannot be imported while a sale or challenge is arranged.
• The bill does not provide cost estimates beyond the $5 million authorization; it is unclear whether that funding covers the full administrative burden on FDA, HHS, and Customs.
• The definitions of “owned or controlled” and of what counts as “support” or being “subject to the jurisdiction” of the PRC may be hard to apply in practice, creating legal uncertainty for companies and regulators.
• Requiring Customs to destroy refused drugs without the opportunity for export may raise questions about waste and costs, especially for drugs that could be sold elsewhere.
• The bill does not specify how FDA should treat previously approved applications beyond review and listing for Customs; it is unclear whether and how existing U.S. approvals would be rescinded or limited in other ways.